Back to Search
Start Over
Evidence for the Positive Impact of Centralization in Esophageal Cancer Surgery.
- Source :
-
Annals of surgery [Ann Surg] 2024 Nov 01; Vol. 280 (5), pp. 772-779. Date of Electronic Publication: 2024 Aug 13. - Publication Year :
- 2024
-
Abstract
- Objective: To analyze the impact of centralization on key metrics, outcomes, and patterns of care at the Irish National Center.<br />Background: Overall survival rates for esophageal cancer in the West have doubled in the last 25 years. An international trend towards centralization may be relevant; however, this model remains controversial, with Ireland centralizing esophageal cancer surgery in 2011.<br />Methods: All patients (n=1245) with adenocarcinoma of the esophagus or junction treated with curative intent involving surgery, including endoscopic surgery, were included (n=461 from 2000 to 2011, and 784 from 2012 to 2022). All data entry was prospectively recorded. Overall survival was measured (1) for the entire cohort, (2) for patients with locally advanced disease (cT 2-3 N 0-3 ), and (3) for patients undergoing neoadjuvant therapy. All complications were recorded as per Esophageal Complication Consensus Group definitions, and the Clavien-Dindo severity classification. Data were analyzed using GraphPad Prism (v.6.0) for Windows and SPSS (v.23.0) software (SPSS) R Studio (R version 4.2.2). Survival times were calculated using a log-rank test and Cox regression analysis, and Kaplan-Meier curves were generated.<br />Results: Endotherapy for cT1a/intramucosal cancer adenocarcinoma increased from 40 (9% total) to 245 (31% total) procedures between the pre-centralization and post-centralization (post-C) periods. A significantly ( P < 0.001) higher proportion of patients with cT 2-3 N 0-3 disease in the post-C period underwent neoadjuvant therapy (66% vs 53%). Operative mortality was lower ( P =0.02) post-C, at 2% versus 4.5%, and ≥IIIa Clavien-Dindo major complications decreased from 33% to 25% ( P < 0.01). Recurrence rates were lower post-C (38% vs 53%, P < 0.01). Median overall survival was 73.83 versus 47.23 months in the 2012 to 2022 and 2000 to 2011 cohorts, respectively ( P < 0.001). For those who received neoadjuvant therapy, the median survival was 28.5 months pre-centralization and 42.5 months post-C ( P < 0.001).<br />Conclusions: These data highlight improvements in both operative outcomes and survival from the time of centralization, and a major expansion of endoscopic surgery. Although not providing proof, the study suggests a positive impact of formal centralization with governance on key quality metrics and an evolution in patterns of care.<br />Competing Interests: The authors report no conflicts of interest.<br /> (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Subjects :
- Humans
Male
Female
Aged
Middle Aged
Ireland epidemiology
Survival Rate
Neoadjuvant Therapy
Adult
Centralized Hospital Services organization & administration
Aged, 80 and over
Postoperative Complications epidemiology
Retrospective Studies
Treatment Outcome
Esophageal Neoplasms surgery
Esophageal Neoplasms mortality
Esophageal Neoplasms therapy
Adenocarcinoma surgery
Adenocarcinoma mortality
Adenocarcinoma therapy
Esophagectomy
Subjects
Details
- Language :
- English
- ISSN :
- 1528-1140
- Volume :
- 280
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Annals of surgery
- Publication Type :
- Academic Journal
- Accession number :
- 39140599
- Full Text :
- https://doi.org/10.1097/SLA.0000000000006487